New research from the Royal Pharmaceutical Society of Great Britain (RPSGB) could shed light on the reasons behind the poor state of men’s health in Britain.
Men’s health - the facts
Published in November 12th, 2008
Comments Off
New research from the Royal Pharmaceutical Society of Great Britain (RPSGB) could shed light on the reasons behind the poor state of men’s health in Britain.
Men’s health - the facts
Published in November 12th, 2008
Comments Off
New research from the Royal Pharmaceutical Society of Great Britain (RPSGB) could shed light on the reasons behind the poor state of men’s health in Britain.
Men’s health - the facts
Published in November 12th, 2008
Comments Off
New research from the Royal Pharmaceutical Society of Great Britain (RPSGB) could shed light on the reasons behind the poor state of men’s health in Britain.
Phosphagenics’ diclofenac enters trial phase in humans
Published in November 12th, 2008
Comments Off
Phosphagenics Limited (”Phosphagenics”) announced today that it has initiated a phase 1 human clinical trial using its patented drug delivery system, TPM, for the targeted delivery of a leading non steroidal anti-inflammatory drug (NSAID), diclofenac.
Phosphagenics’ diclofenac enters trial phase in humans
Published in November 12th, 2008
Comments Off
Phosphagenics Limited (”Phosphagenics”) announced today that it has initiated a phase 1 human clinical trial using its patented drug delivery system, TPM, for the targeted delivery of a leading non steroidal anti-inflammatory drug (NSAID), diclofenac.
Phosphagenics’ diclofenac enters trial phase in humans
Published in November 12th, 2008
Comments Off
Phosphagenics Limited (”Phosphagenics”) announced today that it has initiated a phase 1 human clinical trial using its patented drug delivery system, TPM, for the targeted delivery of a leading non steroidal anti-inflammatory drug (NSAID), diclofenac.
Phosphagenics’ diclofenac enters trial phase in humans
Published in November 12th, 2008
Comments Off
Phosphagenics Limited (”Phosphagenics”) announced today that it has initiated a phase 1 human clinical trial using its patented drug delivery system, TPM, for the targeted delivery of a leading non steroidal anti-inflammatory drug (NSAID), diclofenac.
Transdermal Diclofenac enters Phase 1 Clinical Trial in Humans
Published in November 12th, 2008
Comments Off
Phosphagenics Limited (”Phosphagenics”) (ASX: POH; OTCQX: PPGNY) announced today that it has initiated a phase 1 human clinical trial using its patented drug delivery system, TPM, for the targeted delivery of a leading non steroidal anti-inflammatory drug (NSAID), diclofenac.
NicOx’ Naproxcinod Shows Highly Significant Reduction in Daytime Blood Pressure Versus Naproxen
Published in November 12th, 2008
Comments Off
NicOx S.A. (Euronext Paris: COX) today announced that a new analysis of the data from the 104 Ambulatory Blood Pressure Monitoring (ABPM) study for naproxcinod was presented yesterday at the American Heart Association Scientific Sessions 2008, in New Orleans, USA.